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Abstract 
Objective: Understand the effect of a health messaging intervention focused on provider 
communication about vaccination on mothers’ willingness to vaccinate children against HPV 
and seasonal influenza. 
Methods: 2,476 mothers of 9-13-year-olds in the U.S. completed a Web-based survey in August 
2014. Mothers were randomized to one of two groups targeting HPV or influenza 
vaccine. Mothers whose child had not received the target vaccine (i.e., zero doses of HPV 
vaccine/no prior-year administration of influenza vaccine) were randomized to the 
intervention. The study used a 3x2 between-subjects design; illustrated vignettes depicted one 
of three levels of provider recommendation strength (brief mention of vaccination, strong 
recommendation of vaccination, or personal disclosure of vaccination of own children), and 
presence or absence of information comparing safety of vaccination to the safety of a common 
daily activity. Outcome was mothers’ willingness to have their child receive the target vaccine 
(0-100.) Perceived benefits of vaccination were assessed prior to viewing the intervention and 
included as a covariate in analyses, along with child gender.  
Results: For HPV vaccine, there was a main effect of safety information, F(1,684)=7.99, 
p=.005, and perceived benefits of vaccination, F(1,684)=221.64, p<.001) on mothers’ 
willingness to vaccinate. For influenza, perceived benefits of vaccination significantly related to 
willingness, F(1,462)=105.78, p<.001). Child gender was not associated with willingness. 
Conclusions: Provider communication about vaccination may need to be tailored to the vaccine 
in question. A next step to increasing coverage for both HPV and influenza vaccines may be an 
intervention aimed at increasing mothers’ perceived benefits of vaccination.  
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What’s New?  
 
We found that mothers of non-vaccinated children reported lower willingness to vaccinate 
against influenza than HPV. Viewing information about the relative safety of vaccination 
compared to common daily activities increased mothers’ willingness to vaccinate against HPV 
only.  
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The Advisory Committee on Immunization Practices (ACIP) recommends that the human 
papillomavirus vaccine be routinely administered to early adolescents (i.e., 11–12-year-olds) in 
the United States, while influenza (flu) vaccination is recommended annually for children 
starting at 6 months of age.1 Healthy People 2020 goals for vaccine coverage include 80% of 
individuals receiving at least 3 doses of the HPV vaccine by age 13-15, as well as 70% of 
children aged 6 months through 17 years being vaccinated annually against seasonal flu.2 
Nationwide surveillance data from 2013 indicates that only 37.6% of females and 13.9% of 
males aged 13-17 had completed the HPV vaccine series in 2013, while 57.3% of females and 
34.6% of males had received at least 1 dose of the vaccine.3 Coverage estimates for the flu 
vaccine during the 2013-2014 season were 61% for 5-12 year olds and 46% for 13-17 year olds.4  
Low HPV and flu vaccination rates among adolescents are concerning, given the public 
health implications of these viruses. Vaccination provides effective protection for males and 
females against HPV infection,5 which is the primary cause of cervical cancer and leading cause 
of other anogenital and oropharyngeal cancers, in addition to causing genital warts.6 Three HPV 
vaccines available at the time of the study protect against two HPV types (HPV16 and 18) 
associated with the majority of HPV-related cancers. The quadrivalent vaccine also protects 
against HPV6 and HPV11, which are associated with 90% of genital warts. The nine-valent 
vaccine provides protection against HPV6, HPV11, and five additional oncogenic types.7 
Annual vaccination is the primary strategy for preventing transmission of seasonal flu. 
The vaccine is developed annually to target specific flu viruses predicted to be most common 
during the upcoming season.8 Flu viruses can lead to mild to severe illness, worsening of other 
chronic medical conditions, and even death. The flu vaccine can also reduce symptom severity if 
a vaccinated individual does contract a flu virus.    
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Healthcare provider recommendation is consistently cited as a primary reason that 
parents vaccinate or intend to vaccinate their adolescent children.9-11 Parental health beliefs, such 
as perceived benefits or side effects of vaccination,9,12-14 as well as perceived social norms 
regarding vaccination,13,15 can either promote or hinder vaccination among adolescents. When 
parents’ health beliefs serve as a barrier to vaccination, recommendation from a healthcare 
provider may help to modify these beliefs, resulting in vaccine initiation.16,17 
Given this influence of healthcare provider recommendation, intervention research 
targeting methods for improving the effectiveness of provider communication with patients and 
parents about vaccination may be key for increasing vaccine coverage.9,14,18,19 Strategies may 
include providing presumptive recommendations for vaccination,16 addressing parental concerns 
about the safety of vaccination,20 or sharing personal experiences with parents (e.g., sharing that 
they have chosen to vaccinate their own children).17 
Previous research suggests that viewing health messages about vaccination can affect 
parents’ willingness to vaccinate their children,21,22 although these messages have not 
specifically focused on healthcare provider communication. Health messages have typically 
included information comparing risks from the vaccine-preventable disease to vaccine-related 
risks (i.e., side effects). To our knowledge, vaccine-related risk information has not been 
compared to risk of harm from other common childhood activities, such as involvement in youth 
sports.   
The objective of this study was to determine whether mothers’ willingness to vaccinate 
their children against HPV or flu could be affected by viewing health message vignettes 
depicting an interaction between a healthcare provider and mother. Specifically, we explored 
whether vignettes depicting varying levels of strength of recommendation by the provider and/or 
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provider discussion of vaccine safety (i.e., presence/absence of relative safety information about 
common daily activities, such as sports) increased mothers’ willingness to vaccinate their 
children relative to a brief presumptive recommendation for vaccination by the provider. We also 
examined whether any effect of viewing the vignettes remained after adjusting for mothers’ pre-
existing beliefs about the benefits of vaccination.  
 
Methods 
Sample + Procedure 
Participants were mothers or female legal guardians of 9-13-year-olds living in the 
United States. We chose to collect survey data from mothers, as they are more likely than other 
caregivers to be primary decision makers regarding children’s healthcare,23 and maternal report 
of HPV vaccination status may be more accurate than reports from other caregivers.24,25 We 
targeted mothers of 9-13-year-old males and females, as this includes all children within the 
targeted age range for routine HPV vaccination (ages 11–12), slightly older children eligible for 
“catch up” HPV vaccination (age 13), and younger children eligible to receive the HPV vaccine 
(ages 9–10) prior to the age of routine recommendation. Additionally, rates of flu vaccination 
begin to decline within this age range.4  
The study protocol was approved by the institutional review board at Indiana University 
– Purdue University Indianapolis and granted exempt status. Data were collected in August 
2014. Participants were recruited through Survey Sampling International (SSI), a survey research 
company that maintains a national panel of over 4 million individuals in the United States.26 
Each panel member may participate in up to four surveys annually, and respondents are entered 
into a lottery to win a monetary prize through SSI. E-mail invitations were sent at random by SSI 
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to members of SSI’s U.S. panel meeting the study’s target demographic (i.e., mothers or female 
legal guardians of a 9-13-year-old child living in their household). Initially, 3,208 panelists 
responded to the generic e-mail invitation to participate in a survey by clicking the link directing 
them to the Web-based survey, which was housed on the authors’ university server. After being 
presented with a brief description of the study, 2,860 women (89%) agreed to complete the 
survey. Of these participants, 26 elected to withdraw from the study throughout the course of the 
survey; 2,476 of the remaining women met eligibility criteria for participation (i.e., were at least 
18 years old and the mother or female legal guardian of at least one 9-13-year-old child). 
Participants with more than one 9–13-year-old child were prompted to answer questions about 
their youngest child in this age range. Although the participants were recruited nationally, the 
sample does not constitute a nationally representative sample. 
 
Experimental Design 
All participants provided basic information about their child’s HPV and flu vaccination 
history and were then randomized to either an HPV- or flu-targeted group to receive additional 
survey items focused on that target vaccine (Figure 1). Following randomization into the targeted 
vaccine group, participants whose child had not received the target vaccine (or no prior-year 
administration for the flu-targeted group) were presented with basic information on the target 
vaccine and the medical condition prevented by the target vaccine. They were then randomly 
assigned with equal allocation to one of six health messaging interventions, based on a 3 x 2 
between-subjects factorial design (strength of recommendation x safety information). All 
randomization occurred using the built-in randomization function with equal presentation to 
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groups provided by the Qualtrics survey tool used to design the web-based survey (Qualtrics, 
Provo, UT). 
Health messages were presented as illustrated vignettes depicting a female healthcare 
provider speaking to a mother (Figure 2). Displayed text was individualized to reflect the gender 
of the participant’s child. Participants were first shown the image described above, accompanied 
by the following text: “Now, please imagine you are at your next appointment with your 
[son/daughter]’s healthcare provider. During your visit, the provider mentions that your 
[son/daughter] is due to receive the four vaccines routinely recommended for young 
adolescents.” The introductory vignette was followed by an additional vignette representing one 
of three levels of strength of provider recommendation for vaccination—brief mention (Figure 
2A), strong recommendation (Figure 2B), or strong recommendation plus personal disclosure 
(Figure 2C, with the 2nd panel presented following presentation of the 1st panel). The next 
component of the health messaging intervention consisted of either the presence or absence of 
information regarding the relative safety of vaccination compared to participation in common 
youth activities, such as soccer or basketball (Figure 2D).27-29 The health messages did not focus 
on a specific vaccine but broadly referred to all four vaccines routinely recommended for 
adolescents.  
  
Measures 
Child’s HPV vaccination history was measured using participant report of the number of 
HPV shots her child had received (i.e., 0–3).  Child’s flu vaccination history was measured based 
on participant report of whether the child had received the flu vaccine during the most recent flu 
season, specified as approximately September 2013-March 2014 (i.e., yes or no). Responses of 
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“don’t know” regarding vaccine history were treated as missing; those participants were not 
randomized to receive the health messaging intervention.  
Participant beliefs regarding general benefits of vaccination were measured using the 
following five items with a five-point Likert scale ranging from 1 (strongly disagree) to 5 
(strongly agree): “It is important that people get vaccinated so that they can protect their health,” 
“It is safe for a person to get a vaccine,” “If a person gets too many vaccines, it can ruin his/her 
immune system,” “New vaccines might be unsafe,” and “People don’t need vaccines unless they 
are currently at risk for getting the disease.” The latter three items were reverse coded so that 
higher scores on all items reflected stronger beliefs in the benefits of vaccination. The mean of 
the five items was calculated for use in the analyses (Cronbach’s α = .78). The scale has been 
used previously in research with parents of early adolescents and shown to have predictive 
validity, in that it correlates with parents’ intent to vaccinate against HPV as well as first-dose 
acceptance.12 Mothers’ perceived benefits of vaccination were assessed subsequent to providing 
information on the child’s vaccination history but prior to viewing the health messaging 
intervention.  
Participants provided sociodemographic information, including participant’s age; child’s 
age, biological sex, and race/ethnicity; and geographic region of residence, which was 
determined based on the participant’s reported ZIP code and categorized according to U.S. 
census region (i.e., south, midwest, west, and northeast). 
The primary outcome was participant willingness to have her child receive the target 
vaccine. Immediately following the messaging intervention, participants responded to the 
prompt, “How willing would you be to get [child’s name] vaccinated against [HPV/the flu] 
during this visit, if the vaccine was free and available at the healthcare provider’s office?” using 
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a response scale ranging from 0 (definitely would not) to 50 (undecided) to 100 (definitely 
would). Participants indicated their response using a continuous sliding bar scale, with multiples 
of 10 demarcated as a visual guide. This measure has been used previously to measure parental 
vaccine acceptability/willingness to vaccinate30 and reflects how people naturally understand 
concepts of probability and likelihood. We elected to measure willingness to vaccinate with no 
cost, as the two target vaccines are available free of charge to most children through the Vaccine 
for Children Program or under the preventive services requirements of the Affordable Care 
Act.31,32  
 
Statistical Analysis 
We first tested for differences in sociodemographic characteristics and vaccine attitudes 
across the health messaging groups, using Pearson chi-square tests for categorical variables and 
one-way analysis of variance (ANOVA) for continuous variables.  Using analysis of covariance 
(ANCOVA), we then tested for the main and interactive effects of the two experimental factors 
(strength of recommendation and presence of relative safety information). Perceived benefits of 
vaccination and child gender were included as covariates in the model. Effects were analyzed 
separately by target vaccine group, as we were interested in the effect of the health messaging 
intervention on willingness to vaccinate, rather than the effect of being randomized into one of 
the vaccine groups. Analyses were performed using SPSS version 24. For the flu-targeted group, 
a sample size of 468 (e.g., minimum of 78 participants in each group) provided us with 83.3%, 
89.9%, and 83.3% power to detect an effect size of 0.15 for strength of recommendation, 
presence of relative safety information, and their interaction, respectively. For the HPV-targeted 
group, a sample size of  684 (e.g., minimum of 114 in each group) provided us with 94.8%, 
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97.5%, and 94.8% power to detect an effect size of 0.15 for strength of recommendation, 
presence of relative safety information, and their interaction, respectively. 
 
Results 
The mean age of participants was 38.0 years (SD=8.2). Slightly over half (56.7%) of 
target children were female, with a mean age of 10.6 years (SD=1.4). Child race/ethnicity was 
reported as follows: White, 71.6%; African American, 13.7%; Hispanic or Latino; 12.7%; Asian; 
4.8%; American Indian; 2.3%; Native Hawaiian/Pacific Islander, 0.9%; and other, 1.8%. 
Participants were instructed to select all applicable options. For analyses, race/ethnicity was 
coded as follows: non-minority, 65.2% (endorsing “White” only), and minority, 34.8% 
(including any participants endorsing at least one racial or ethnic category other than “White”).  
Geographic region of residence was reported as follows: South, 37.8%; Midwest, 23.4%; West, 
20.7%; and Northeast, 18.2%. 
HPV and flu vaccination history were missing for 97 and 89 participants, respectively; 
194 and 24 participants provided a response of “don’t know” regarding HPV and flu vaccine 
history, respectively, and were excluded from the intervention. Among participants providing 
vaccination history data, 34.9% reported that their child had received at least one dose of the 
HPV vaccine, and 56.3% reported that their child had received the flu vaccine during the 
previous flu season.  
The mean score for perceived benefits of vaccination was 3.53 (SD=0.78; range 1-5), 
reflecting overall neutral-to-positive beliefs about the benefits of vaccination.  
Sample characteristics are shown for the HPV-targeted group (Table 1) and the flu-
targeted group (Table 2). Within each target group, data are first presented by vaccination status 
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and then arranged by the 6 possible health messaging groups into which participants whose child 
had not received the target vaccine were randomized. For both target groups, participants’ 
sociodemographic characteristics and perceived benefits of vaccination did not differ 
significantly among the six messaging groups (all ps > .05).  
Among participants who were randomized to the HPV-targeted group and whose child 
had not already received at least 1 dose of the HPV vaccine (i.e., 58.5% of randomized 
participants; see Figure 1), mean willingness to have the child receive the HPV vaccine was 59.7 
(SD = 35.4, range 0-100). Among participants randomized to the flu-targeted condition and 
whose child had not received the flu vaccine during the previous flu season (i.e., 39.8% of 
randomized participants), mean willingness to have the child receive the flu vaccine was 50.6 
(SD=35.9, range 0-100). An independent samples t-test indicated that this difference in mean 
willingness between target groups was statistically significant, t(1160)=4.26, p<.001. 
 For the HPV-targeted group, ANCOVA results indicated a significant main effect of 
viewing information regarding the relative safety of vaccination on participants’ willingness to 
vaccinate their child against HPV, F(1,684) = 7.992, p = .005, partial η2=.012. This effect is 
illustrated in Figure 3.  Strength of recommendation did not have a significant main effect on 
participant willingness to vaccinate against HPV, and there were no significant interaction 
effects between factors. Perceived benefits of vaccination was significantly related to 
participants’ willingness to vaccinate their child against HPV, F(1,684) = 221.641 p < .001, 
partial η2=.245. Child gender was not significantly associated with willingness to vaccinate.  
 For the flu-targeted group, ANCOVA results indicated no significant main effects of 
either safety information or strength of recommendation on participant willingness to vaccinate 
the child against flu. There were no significant interaction effects. Perceived benefits of 
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vaccination, however, was significantly related to participants’ willingness to vaccinate, F(1,462) 
= 105.783, p < .001, partial η2=.186. Child gender was not significantly associated with 
willingness to vaccinate. 
 For each target group, we conducted a sensitivity analysis in which we explored whether 
pre-existing perceived benefits of vaccination might moderate the effect of health messaging 
intervention on willingness to vaccinate (i.e., whether the intervention was more or less effective 
among mothers with varying perceptions of vaccine benefits), rather than including this variable 
as a continuous covariate, as in the main analyses. In this sensitivity analysis, we categorized 
participants into three groups based on their perceived benefits of vaccination score: “low” 
(score < 3; 21.2%), “middle” (score ≥ 3 and < 4; 47.2%), and “high” (score ≥ 4; 31.6%). The 
categorical vaccine attitudes variable did not have a significant main effect on participant 
willingness to vaccinate in either target vaccine group, and there were no significant interactions 
between vaccine attitudes and the other factors. 
We also conducted additional sensitivity analyses in which we explored the potential 
moderating effect of child age on participant willingness to vaccinate (i.e., whether the 
intervention was more or less effective depending on the age of the target child). When included 
as a continuous covariate in the full models described in the main analyses, age was not 
significantly related to participant willingness to vaccinate in either target group. When included 
in the full ANCOVA model as an additional categorical factor (dichotomized as “age 9–10” vs. 
“ages 11–13”), there was no main effect of age group nor any interactive effects between age 
group and the other factors. 
 
Discussion 
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Mothers’ willingness to vaccinate differed by target vaccine. Specifically, mothers of 
non-flu-vaccinated children showed lower overall willingness to receive that vaccine when 
compared to mothers with non-HPV-vaccinated children and their willingness to receive the 
HPV vaccine. Mothers of non-HPV-vaccinated children were influenced by viewing health 
messages presenting relative risk information, as indicated by an increase in willingness to 
vaccinate. In contrast, the smaller group of mothers of non-flu-vaccinated children were not 
influenced by the intervention.  
 Several factors could explain this relative resistance among flu non-vaccinators. The low 
rate of HPV vaccination relative to influenza vaccination may have provided more opportunity 
for change in maternal attitude toward HPV vaccination. Flu vaccine is recommended annually 
to children and adults, and mothers who choose not to vaccinate their children against the flu 
regularly may routinely refuse the vaccine for themselves or children or perceive more negative 
effects of the vaccine. In contrast, mothers who have not vaccinated their children against HPV 
may be less familiar with HPV vaccine and may be more open to vaccination when they do 
receive information from their health care provider.  
In contrast to prior studies highlighting the effect of provider recommendation on parent 
acceptance of HPV vaccine, we found no effect of strength of provider recommendation on 
mothers’ willingness to vaccinate. This finding may be an artifact of our visual presentation of 
health messages, while the power of physician recommendation may derive from the face-to-face 
encounters with a child’s personal physician with whom the family has an established 
relationship.  
 We also found no effect of viewing a health message in which a physician disclosed that 
she had vaccinated her own child on mothers’ willingness to vaccinate against either vaccine. 
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Again, this may be a function of the generic message bearer in our health message vs. the 
potential influence of disclosure in a face-to-face patient encounter. A systematic review of 
physician disclosure of personal information33 reported mixed effects, with pediatricians 
employing self-disclosure more often than adult providers. Physicians seem to believe that 
personal messages about what they would do for their own children are an effective 
communication strategy for persuading vaccine-hesitant parents.17 To our knowledge, this is the 
first study to examine the impact of physician self-disclosure of personal vaccination practices 
on parents’ willingness to vaccinate. 
Observed differences in intervention effects on willingness to vaccinate against the flu 
compared to HPV suggest that health communication approaches may need to differ by vaccine 
type. We found that comparing the relative safety of vaccination to the risk of harm from 
participating in common, everyday youth activities, such as sports, increased mothers’ 
willingness to vaccinate their non-vaccinated children against HPV but not the flu.  Most health 
messages targeting risk perception compare risk of side effects from receiving a vaccine to risks 
associated with the child getting the disease if he/she remains unvaccinated. To our knowledge, 
this is the first study to evaluate the impact of providing relative risk information about everyday 
child experiences on parents’ willingness to vaccinate. Parents’ inaccurate beliefs about potential 
side effects may be more entrenched for the flu vaccine (e.g., “people get sick from the flu after 
getting the flu vaccine”) than for HPV vaccine and therefore less  malleable when presented with 
new risk information. In our study, only pre-existing attitudes about the general benefits of 
vaccination were associated with willingness to vaccinate children against the flu, suggesting 
that interventions targeting perceived benefits of vaccination may have the most “bang for the 
buck” when it comes to increasing flu vaccine coverage. 
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The study has several limitations. Data were not collected from a nationally 
representative sample; however, sample demographics were comparable to concurrent U.S. 
census estimates of the distributions of individuals across geographic regions and of racial 
groups among 9–13-year-olds,34, 35 and the HPV vaccine initiation rate among 13-year-olds in 
our 2014 sample was similar to coverage estimates for 13-year-olds in the 2014 NIS-Teen 
sample.34,36 Our outcome measured willingness to vaccinate, and medical records documenting 
subsequent vaccination behavior were unavailable, limiting generalizability to real-world 
vaccination uptake. However, intention research in the behavioral intervention domain can be 
viewed as an analogue to animal model studies in the biomedical research domain.37 As such, 
our study represents an important preliminary step in developing and improving interventions to 
improve childhood vaccine uptake. 
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Table 1. Sample characteristics as distributed across health messaging conditions, HPV-targeted group 
    
Health Messaging Condition 
 
Vaccination Status 
 
No Safety  Safety 
 
 
Initiated 
Not 
Initiated 
 
Brief 
Mention 
Strong 
Rec 
Personal 
Disclosure 
 Brief 
Mention Strong Rec 
Personal 
Disclosure  p  
Measure (n =396) (n=701)  (n=116) (n=116) (n=116)  (n=114) (n=115) (n=116)   
Child's age, n 396 700 
 
116 116 116 
 
113 115 116 
    
0.599  
Mean ± SD 11.0 ± 1.4 10.5 ± 1.4 
 
10.5 ± 1.4 10.4 ± 1.3 10.6 ± 1.3  10.7 ± 1.4 10.4 ± 1.4 10.4 ± 1.3 
 
Child's gender, n 396 701 
 
116 116 116 
 
114 115 116 
   
0.596  
Male, % 35.6% 42.1% 
 
45.7% 44.0% 38.8%  36.0% 42.6% 45.7% 
 Female, % 64.4% 57.9% 
 
54.3% 56.0% 61.2%  64.0% 57.4% 54.3% 
 
Child's race/ethnicity, n 384 686 
 
114 116 114 
 
113 114 115 
   
0.473  
Minority race/ethnicity, % 42.4% 28.7% 
 
32.5% 24.1% 25.4%  34.5% 27.2% 28.7% 
 Non-minority race/ethnicity, % 57.6% 71.3% 
 
67.5% 75.9% 74.6%  65.5% 72.8% 71.3% 
 Mother's age, n 396 701 
 
116 116 116  114 115 116 0.216  
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Mean ± SD 37.7 ± 7.8 39.1 ± 8.4 
 
38.0 ± 8.2 38.9 ± 7.2 40.8 ± 10.4  38.6 ± 7.7 39.1 ± 7.8 39.5 ± 8.6 
 
Geographic region, n 386 688 
 
114 116 115 
 
113 114 116 
   
0.532  
Northeast, % 22.0% 17.6% 
 
18.4% 17.2% 13.9%  16.8% 21.9% 17.2% 
 Midwest, % 24.4% 24.7% 
 
17.5% 28.4% 27.8%  28.3% 21.1% 25.0% 
 South, % 33.4% 39.4% 
 
42.1% 36.2% 41.7%  31.9% 43.9% 40.5% 
 West, % 20.2% 18.3% 
 
21.9% 18.1% 16.5%  23.0% 13.2% 17.2% 
 Perceived benefits of vaccination, 
n 396 701 
 
116 116 116 
 
114 115 116 
  
0.112  
Mean ± SD 3.6 ± 0.7 3.5 ± 0.8 
 
3.4 ± 0.9 3.7 ± 0.8 3.4 ± 0.8  3.5 ± 0.8 3.5 ± 0.8 3.5 ± 0.8 
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Table 2. Sample characteristics as distributed across health messaging conditions, influenza-targeted group 
    
Health Messaging Condition 
 
Vaccination Status 
 
No Safety 
 
Safety 
 
 
Received 
Did not 
Receive 
 
Brief 
Mention 
Strong 
Rec 
Personal 
Disclosure 
 
Brief 
Mention 
Strong 
Rec 
Personal 
Disclosure p 
  (n = 699) (n = 475)   (n = 78) (n = 79) (n = 78)   (n = 79) (n = 79) (n = 79)   
Child's age, n 698 474 
 
78 79 77 
 
79 79 79 0.414 
Mean ± SD 10.6 ± 1.4 10.6 ± 1.4 
 
10.5 ± 1.3 10.6 ± 1.4 10.8 ± 1.4 
 
10.8 ± 1.5 10.7 ± 1.5 10.4 ± 1.2 
 Child's gender, n 699 475 
 
78 79 78 
 
79 79 79 0.149 
Male, % 42.8% 50.1% 
 
43.6% 55.7% 57.7% 
 
50.6% 39.2% 53.2% 
 Female, % 57.2% 49.9% 
 
56.4% 44.3% 42.3% 
 
49.4% 60.8% 46.8% 
 Child's race/ethnicity, n 690 463 
 
77 77 77 
 
78 76 78 0.889 
Minority race/ethnicity, % 39.0% 29.2% 
 
32.5% 27.3% 26.0% 
 
28.2% 27.6% 33.3% 
 Non-minority race/ethnicity, % 61.0% 70.8% 
 
67.5% 72.7% 74.0% 
 
71.8% 72.4% 66.7% 
 Mother's age, n 475 699 
 
78 79 78 
 
79 79 79 0.815 
Mean ± SD 37.5 ± 8.6 37.8 ± 7.7 
 
37.6 ± 8.3 37.9 ± 7.1 37.4 ± 7.4 
 
38.9 ± 7.7 38.0 ± 8.9 37.2 ± 6.6 
 Geographic region, n 691 464 
 
77 78 77 
 
78 77 77 0.943 
Northeast, % 19.8% 13.8% 
 
15.6% 12.8% 14.3% 
 
17.9% 10.4% 11.7% 
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Midwest, % 18.4% 27.2% 
 
27.3% 33.3% 27.3% 
 
20.5% 31.2% 23.4% 
 South, % 39.4% 37.1% 
 
32.5% 35.9% 37.7% 
 
39.7% 35.1% 41.6% 
 West, % 22.1% 22.0% 
 
24.7% 17.9% 20.8% 
 
21.8% 23.4% 23.4% 
 Perceived benefits of vaccination, n 699 475 
 
78 79 78 
 
79 79 79 0.879 
Mean ± SD 3.7 ± 0.7 3.3 ± 0.8   3.3 ± 0.8 3.2 ± 0.9 3.4 ± 0.8   3.3 ± 0.8 3.4 ± 0.8 3.3 ± 0.8   
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
Figure 1. Enrollment, allocation to target group, randomization to intervention, and analysis. 
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Figure 2. Vignettes presented as part of health messaging intervention. A, Brief mention vignette. B, 
Strong recommendation vignette. C, Personal disclosure vignette. D, Relative safety vignette. Text was 
individualized based on the gender of the target child; vignettes shown are for target daughters. 
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Figure 3. Reported willingness to vaccinate child against HPV on a scale of 0–100 among 
mothers in the HPV-targeted group, by presence of relative safety information about vaccination. 
Mean scores shown, with error bars representing ± 1 SE. 
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